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ABSTRACT 
Background: Recent recommendations from the Group for the Respect of 
Excellence and Ethics in Science for the clinical assessment of the effects of 
disease-modifying osteoarthritis (OA) drugs suggest hat improvement in joint 
space narrowing, pain, and function relative to a control group should be the 
primary end points. 
Objective: The aim of this study was to assess the ability of sodium pento- 
san polysulfate (NaPPS) to improve pain and function in patients with OA of the 
knee. 
Methods: This randomized, ouble-blind, placebo-controlled pilot study was 
performed at the Queen Elizabeth II Medical Centre, Perth, Australia. Patients 
aged ___18 years with OA of the knee were randomly assigned to receive NaPPS 
3 mg/kg or Ringer's olution (control), IM QW for 4 weeks. Efficacy was assessed 
at enrollment and weekly during the 4 weeks of treatment and at weeks 8, 12, 16, 
and 24. Seven direct clinical assessments were made, including intensity of early 
morning joint stiffness, pain at rest, and pain on walking. A 10-cm visual analog 
scale (VAS) was used to assess pain at rest and on walking and early morning 
joint stiffness. Response was defined as a change from baseline in VAS score 
___2 cm. Function was assessed using the 10-cm VAS to rate 13 activities of daily 
living (ADLs), including stair climbing and domestic hores. Patient global as- 
sessment of the overall effectiveness of the study drug comprised a 4-point 
Likert scale (0 = not effective to 3 = maximally effective). An aggregate score for 
all ADL functions was calculated as the mean change from baseline score of all 
of the ADLs as determined at 4, 8, 12, 16, and 24 weeks after commencement of 
the study. For tolerability monitoring, hematology and biochemistry were used, 
and patients were questioned about adverse vents at each visit. 
Results: A total of 114 patients were enrolled (83 women, 31 men; mean [SD] 
age, 63.3 [1.5] years; NaPPS group, 54 patients; control group, 60 patients). Sig- 
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nificant differences in scores of 3 of the 7 direct clinical assessments were found 
between the 2 groups (duration of joint stiffness at 4, 8, 12, and 16 weeks [all, P_  
0.015]; pain at rest at 8, 12, 16, and 24 weeks [all, P _ 0.017]; and patient global 
assessment a 4, 8, 12, 16, and 24 weeks [all, P _ 0.006]). The rates of trial con- 
tinuation were higher in the NaPPS group compared with those in the control 
group at 8, 12, and 24 weeks (all, P< 0.05). Mean scores for 3 of 13 ADLs were 
significantly higher in the NaPPS group compared with those in the control 
group at weeks 8 and 12 (all, P _ 0.03). On combining all of the ADL scores, func- 
tional improvement from baseline was found at weeks 8 and 12 in the NaPPS 
group (both, P = 0.02). Mild bruising at the injection site occurred in <1% of 
patients in both treatment groups. 
Conclusions: In this pilot study, 4 weekly injections of NaPPS were associ- 
ated with significantly improved uration of joint stiffness and pain at rest com- 
pared with controls for 20 weeks after the cessation of treatment, and signifi- 
cantly improved pain on walking and overall function for 8 weeks after the 
cessation of treatment in these patients with OA of the knee. (Curt Ther Res Clin 
Exp. 2005;66:552-571) Copyright © 2005 Excerpta Medica, Inc. 
Key words: osteoarthritis, pentosan polysulfate, symptomatic relief. 
INTRODUCTION 
Osteoarthritis (OA) is the most prevalent type of arthritis, affecting >16 million 
individuals aged >65 years in the United States and -70% worldwide. 1-3 In ad- 
dition to the pain and disability associated with OA, enormous ocial and 
economic consequences are augmented as the longevity of the population 
increases. 4-6 
OA is a multifactorial disorder in which aging, genetic, hormonal, and 
mechanical factors are all important contributors to disease onset and progres- 
sion. OA emerges as a clinical syndrome when these etiologic determinants 
converge, resulting in a level of joint injury sufficient o impair function and 
cause stiffness and pain. These clinical symptoms are accompanied by radio- 
logic evidence of joint space narrowing (JSN), subchondral bone sclerosis, and 
osteophytosis at the joint margins. 3 The breakdown of articular cartilage in 
joints affected by OA results in the release of detritus and molecular fragments 
derived from the extracellular matrix into the synovial cavity. Because these 
entities are antigenic, they elicit a secondary synovitis. 7 
In addition to analgesics, the agents most frequently used to treat OA are the 
steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs). However, these 
drugs mainly relieve the symptoms of OA and exhibit negligible beneficial effects 
on the underlying pathology and/or disease progression. 8,9 In fact, some reports 
suggest that some NSAIDs might exacerbate he failure of cartilage and bone in 
arthritic joints by inhibiting cellular repair mechanisms and connective tissue 
homeostasis. 8,9Also, long-term use of NSAIDs has been associated with serious 
adverse ffects in the elderly population, including a high risk for gastrointesti- 
553 
CURRENT THERAPEUTIC RESEARCH 
nal lesions arising from NSAIDs' inhibitory activity on the synthesis of the 
gastroprotective prostaglandins by the cyclooxygenase (COX)-1 enzymatic sys- 
tem. 1°,11 Although newer NSAIDs with selective COX-2 inhibitory activity have 
been associated with a reduced risk for gastrointestinal adverse vents, long-term, 
controlled studies have found an increased risk for thrombosis and myocardial 
infarction associated with their use in susceptible patients with OA. 12-14 
In the past few decades, the concept of disease- (or structural-) modify- 
ing OA drugs (DMOADs) have been explored as an alternative treatment modal- 
ity for OA. 15,16 Such agents were defined by their ability to slow down, arrest, 
or reverse OA disease progression over time. From the standpoint of drug- 
regulatory agencies, DMOADs would be required to reduce the rate of cartilage 
loss in the affected joint, as might be measured by decreased JSN. However, 
this structural change in cartilage would need to correlate with improved 
symptoms. 17Time to total joint replacement has been suggested as an alterna- 
tive efficacy end point and a possible index of positive clinical outcome of 
DMOAD treatment. 17 However, 1 report concluded that time to total joint re- 
placement was not an acceptable primary efficacy end point because it lacked 
specificity. 18 
Pentosan polysulfate (PPS) is a semisynthetic drug manufactured from 
Beechwood hemicellulose by sulfate esterification of the sugar ring hydroxyl 
groups. It has a mean molecular weight (MW) of 5700 Da and a sulfur content of 
-16%. 19 The results from numerous in vitro and animal studies of the polyanion 
sodium PPS (NaPPS) have led to the suggestion that this agent might be classi- 
fied as a DMOAD because of its ability to preserve the integrity of the articular 
cartilage and bone while improving the quality of the joint synovial fluid. 19-21 
Thus, NaPPS supports chondrocyte and fibroblast anabolic activities while 
attenuating catabolic events associated with destruction of the cartilage xtra- 
cellular matrix. 21 Although some of the anticatabolic activities of NaPPS 
have been shown to occur via direct inhibition of enzymes uch as elastase, 
cathepsin-B, and hyaluronidase, 2° 21 this drug can enter chondrocytes and fi- 
broblasts, bind to promoter proteins in the nucleus, and down-regulate g ne ex- 
pression of matrix metalloproteinases. 21 These chondroprotective activities of 
NaPPS have been demonstrated to be effective in rat, rabbit, and canine mod- 
els of OA. 20'21 Moreover, the biosynthesis of high-MW hyaluronan by synovial 
fibroblasts, which is diminished in OA joints, was restored when these cells 
were incubated with NaPPS in vitro or after its intra-articular injection into 
joints of patients with OA. 21 
Despite these laboratory findings, clinical studies to support he classifica- 
tion of NaPPS as a DMOAD are lacking. Based on recommendations from the 
Group for the Respect of Excellence and Ethics in Science, Liege, Belgium, 17,18 
to assess NaPPS as a clinically efficacious DMOAD requires a placebo-controlled, 
double-blind clinical trial of sufficient duration to allow changes in JSN to be 
reliably determined and correlated with improved symptoms. Recent reports 
have suggested that patients with OA recruited into DMOAD clinical trials 
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would need to be moni tored clinically and radiographical ly  for at least 
24 months. 22,23 However, even if such a trial were implemented, the accuracy of 
the radiologic method of assessment could still be quest ioned without an 
assessment of symptom improvement. 24 
The objective of this preliminary study was to assess the effectiveness and 
tolerabil ity of NaPPS in patients with OA of the knee. 
PATIENTS AND METHODS 
Study Design 
This randomized, double-blind, placebo-controlled pilot study was conducted 
at the Queen Elizabeth II Medical Centre, Perth, Australia. The protocol was 
approved by the Human Research Ethics Committee at the center. 
Inclusion and Exclusion Criteria 
Patients were recruited from outpatient rheumatology clinics and databases 
of rheumatologists in private practice by a letter of request from the chief 
clinical investigator (J.E.). Inclusion criteria were age ___18 years, OA of 1 or 
both knees (the grade of OA was determined radiographically using the classi- 
fication criteria of Kellgren and Lawrence25), symptomatic pain at rest and on 
walking and moderate early morning joint stiffness (scores ___4 on a 10-cm 
visual analog scale [VAS] [0 = no diff iculty or pain to 10 = worst imaginable dif- 
f iculty or pain]), wil l ingness to attend follow-up visits, and mild changes on 
radiography indicative of OA using the Kellgren and Lawrence 25 criteria. 
Patients were excluded if they had any other rheumatic condit ion that would 
interfere with assessment (eg, rheumatoid arthrit is or OA of any other lower 
l imb joint, such as the ankle), had current bleeding diathesis or were receiving 
treatment with warfarin, had any other severe condit ion affecting mobi l i ty  (eg, 
cardiac or respiratory disease), had severe changes on radiography indicative 
of OA, and/or were receiving prednisolone or were unable to discontinue treat- 
ment with NSAIDs for any reason. All eligible patients provided written informed 
consent to participate. 
Study Drugs 
After an NSAID washout period of 2 weeks, patients were randomized, in a 
1:1 ratio using a computer-generated able of random numbers, to receive NaPPS 
3 mg/kg or Ringer's solution (control). The NaPPS was provided in sterile, 
injectable vials at a concentrat ion of 100 mg/mL, diluted in water to a volume of 
10 mL. To maintain blinding of the investigators and patients, the Ringer's solu- 
tion was provided at a similar volume in identical vials. All injections were 
administered into the gluteal muscle region of each patient at 1-week intervals 
for 4 weeks (Figure 1). NSAID use was not allowed throughout the study. 
Patients were allowed to use rescue medication (paracetamol [aceta- 
minophen])  when they considered the joint pain to be unbearable. At each 
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2-week NSAID washout period ] 
injection of NaPPS 3 mg/kg or Ringer's solution (control) I 
,_ -  tttt,,, i , , ,  i , , ,  i , , ,  i , , ,  
4 8 12 1 6 Time (wk) 
Treatment Assessment--Direct Measurements 
Early morning joint stiffness (time) 
Early morning joint stiffness (VAS) 
Pain at rest (VAS) 
Pain on walking 30 m (VAS) 
Step time (min) 
Treatment effectiveness (4-point Likert scale) 
Global pain assessment 
24 
Treatment Assessment--ADL Function 
Aggregate score 
Self-dressing 
Getting into and out of bed 
Walking outdoors on flat ground 
Washing and drying self 
Bending to pick up clothing 
Walking upstairs 
Walking downstairs 
Getting into and out of a car 
Rising from sitting 
Walking after rising 
Walking uphill 
Walking downhill 
Doing domestic chores 
Figure 1. Study protocol and timeline used for treatment and assessment in the sodi- 
um pentosan polysulfate (NaPPS) osteoarthritis clinical trial. VAS = 10-cm 
visual analog scale (0 = no difficulty or pain to 10 = worst imaginable diffi- 
culty or pain); ADL = activities of daily living. 
visit, patients were questioned concerning their consumption of NSAIDs or 
paracetamol. 
Efficacy Assessments 
The primary end points in this study were improvement in pain and function. 
Patient assessments included 7 direct clinical measurements, patient global 
assessment, and assessment of function in 13 activites of daily living (ADLs). 
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The direct clinical measurements obtained using the 10-cm VAS included in- 
tensity and duration of early morning joint stiffness, pain at rest, pain on walk- 
ing, and treatment effectiveness. 
Patient global assessment of the overall effectiveness of the study drug com- 
prised a 4-point Likert scale (0 = not effective to 3 = maximally effective). 26 All 
assessments were made at each weekly visit during the 4 weeks of treatment 
and at weeks 8, 12, 16, and 24. 
Each patient completed an ADL function assessment questionnaire consist- 
ing of 13 parameters,  including stair climbing and domestic chores, modified 
from the Western Ontario and McMaster (WOMAC) University Osteoarthrit is 
Index. 26 An aggregate score for all ADL functions was calculated as the mean 
change from baseline score on all of the ADLs as determined at 4, 8, 12, 16, and 
24 weeks after commencement  of the study. 
Clinically important improvement was defined a priori to identify patient char- 
acteristics that might predict who would respond to NaPPS treatment at 4 weeks. 
A relevant response for each parameter was indicated by a _2-cm change from 
baseline in VAS scores for early morning joint stiffness, pain at rest, and pain on 
walking in all affected joints, and a patient global assessment of 3 (maximum 
treatment effectiveness). 
Tolerability Assessments 
For tolerabil ity monitoring, nonfasted blood samples were col lected at base- 
line and at study weeks 4 and 12. Blood was subjected to standard laboratory 
hematologic (full blood count) and biochemical (kidney and liver function) 
analysis. In addition, patients were quest ioned about adverse events (eg, injec- 
tion site reaction, rash, nausea) at each visit. 
Statistical Analysis 
A power analysis determined that to achieve 80% power at an alpha level of 
5%, we would need 180 patients (90 per group) to show a 20% improvement in 
VAS scores for the primary end points. However, in an interim analysis, the re- 
sponse was sufficiently strong in the NaPPS group to suggest hat statistical sig- 
nificance could be achieved with <180 patients. One hundred fourteen patients 
were included in the analyses. 
The number of patients remaining in the study at each visit was recorded, and the 
data were analyzed on an intent-to-treat (ITT) basis, with the last record being car- 
ried forward in the event of loss to follow-up. The ITT analysis was performed to 
adjust for the differential withdrawal rate. Baseline characteristics were compared 
between the 2 groups (NaPPS and control) using the ~2 and Mann-Whitney U sta- 
tistics for categoric and quantitative data, respectively. Nonparametric tests were 
used because data were not normally distributed. Changes from baseline in VAS 
or patient global assessment scores were compared using the Student t test 
(unpaired, 2-tailed). Response rates were compared using the 2-tailed Z test for 
proportions. Differences were considered to be statistically significant at P --- 0.05. 
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RESULTS 
One hundred fourteen patients were enrolled (83 women, 31 men; mean [SD] 
age, 63.3 [1.5] years). The demographic profiles of the 2 treatment groups, con- 
sisting of 54 and 60 patients in the NaPPS and control groups, respectively, are 
shown in Table I. On breaking the randomization codes, no significant differ- 
ences in age, sex, body mass index (BMI), number of involved joints (hips or 
knees), global pain score, or radiographic grade of knee OA were found between 
the 2 groups (Table I). However, the between-group difference in the mean (SE) 
duration of OA symptoms was significant (NaPPS, 5.0 [0.5] years; controls, 6.8 
[0.7] years [P = 0.03]). There were no significant between-group differences in 
rates of ADL functional disability assessed at baseline (Table If). All 114 patients 
completed the 4-week course of injections (weeks 1-4), but some patients were 
withdrawn from the study due to dissatisfaction with treatment or loss to follow- 
up (NaPPS, 24; control, 40). The percentages of patients remaining in the trial 
were significantly higher in the NaPPS group at 8, 12, and 24 weeks compared 
with controls (mean [SE]: NaPPS, 85.2% [4.8%], 61.1% [6.6%], and 55.6% [6.8%], 
respectively; controls, 65.0% [6.2%], 43.3% [6.4%], and 33.3% [6.1%], respec- 
tively [P< 0.01, P< 0.05, and P< 0.01, respectively]) (Table III). 
Table I. Baseline demographic and clinical characteristics of the study patients. 
NaPPS Control 
Parameter (n = 54) (n = 60) 
Age, mean (SE), y 62.5 (1.4) 64.0 (1.6) 
Sex, no. (%) 
Female 42 (77.8) 41 (68.3) 
Male 12 (22.2) 19 (31.7) 
BMI, mean (SE), kg/m 2 29.1 (0.7) 29.3 (0.7) 
Duration of symptoms 
Mean (SE), y 5.0 (0.5)* 6.8 (0.7) 
-<2 y, no. (%) of patients 16 (29.6) 14 (23.3) 
-<5 y, no. (%) of patients 35 (64.8) 31 (51.7) 
No. of joints affected 
Total 87 89 
Mean per patient 1.6 1.5 
% Global pain VAS score ->4, no. (%) of patients 9 (16.7) 1 7 (28.3) 
No. (%) of patients with changes on radiography 
0 Change 0 0 
1 Change 18 (33.3) 15 (25.0) 
2 Changes 0 0 
3 Changes 10 (18.5) 4 (6.7) 
NaPPS = sodium pentosan polysulfate; BMI = body mass index; VAS = visual analog scale. 
*P = 0.03 versus control group. 
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Table II. Baseline functional disability* in activities of daily living 
(ADLs) in patients with osteoarthritis, t Values are percen- 
tages of patients. 
NaPPS Control 
ADL (n = 54) (n = 60) 
Walking upstairs 
Walking downstairs 
Walking downhill 
Walking uphill 
Walking immediately after rising 
Getting into and out of a car 
Rising from sitting 
Doing domestic chores 
Getting into and out of bed 
Walking outdoors on flat ground 
Bending to pick up clothing 
Washing and drying self 
Self-dressing 
96 93 
96 92 
94 87 
94 87 
89 92 
89 87 
89 87 
81 77 
67 63 
44 38 
13 8 
5 10 
5 5 
NaPPS = sodium pentosan polysulfate. 
*Score _>4 on 10-cm visual analog scale (0 = no pain or difficulty to 10 = worst 
imaginable pain or difficulty). 
tNo significant between-group differences were found. 
Direct Measurement  Parameters 
The duration of early morning joint stiffness was significantly less in the 
NaPPS group at weeks 4, 8, 12, and 16 (all, P _< 0.015) (Figure 2A). In patients 
treated with NaPPS whose baseline VAS score for pain at rest was _>2 cm (ITT 
population [36 patients]), the mean VAS score did not show discrimination 
from that in the control group until week 8 (P = 0.016), and the VAS reduction 
of 0.5 lasted at least 16 weeks thereafter (all, P _< 0.017) (Figure 2B). On sta- 
tistical analysis of pain on walking, using the absolute VAS as the control, no 
statistically significant differences were found at any time point (data not 
shown). However, using the response rate analysis for VAS score _>2, a statis- 
tically higher proportion of patients had improvement in pain on walking in 
the NaPPS group (range, 35.2%-50.0%) compared with the control group 
(range, 16.7%-25.0%) at 4, 12, and 24 weeks (P = 0.001, P = 0.02, and P = 0.02, 
respectively) (Table III). 
Patient global assessment of treatment effectiveness was significantly high- 
er in the NaPPS group compared with the control group at all time points after 
the fourth injection (all, P _< 0.006) (Figure 3). The percentage of patients 
reporting maximal effectiveness was significantly greater in the NaPPS group 
compared with the control group at all time points (all, P _< 0.01); however, 
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Figure 2. 
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Time (wk) 
Changes from baseline in (A) duration of early morning joint stiffness and 
(B) pain at rest on a 10-cm visual analog scale (VAS) (0 -- no difficulty or pain 
to 10 -- worst imaginable difficulty or pain) after 4-week administration 
of sodium pentosan polysulfate (NaPPS) or Ringer's solution (control) in 
patients with osteoarthritis of the knee. P versus control group: *<0.001; 
t=0.015; ~=0.008; §=0.016; 11=0.014; I=0.017. 
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in the NaPPS group, this effect declined from 33.3% at 4 weeks to 18.5% at 
24 weeks. In contrast, the rate in the control group was 5.0% at 4 weeks and 3.3% 
at 24 weeks (Table llI). 
Subana lys i s  
In the analysis to identify patient characterist ics that might predict who 
would respond to NaPPS treatment at 4 weeks, in the NaPPS-treated group, 
using treatment effectiveness as a marker of response, statistical analysis found 
no significant differences in mean age, sex, mean symptom duration, mean BMI, 
or mean baseline VAS scores for pain on rest and joint stiffness. When respond- 
ers were defined as patients reporting maximum treatment effectiveness, 44.4% 
of responders had mild radiographic hanges (JSN) compared with 33.3% of 
nonresponders,  and 41.7% of responders had Kellgren and Lawrence 25 grade 1 
changes on radiography compared with 26.7% of nonresponders;  these differ- 
ences did not reach statistical significance. Furthermore, there was no differ- 
ence in the percentages of patients in each group whose disease duration was 
---5 years or who were obese (BMI, ---30 kg/m2). Using improved pain on walking 
as a response measure at 4 weeks, no differences in sex, mean age, percentage 
Figure 3. 
Study 
Drug 
Administration 
[ ~ 
= NaPPS (n = 54) 
= Control (n = 60) 
No Study Drug Administration 
1-  t 
.E S 
~ 0 .8 -  * 
EE 
o ~ 0 .6 -  
m@ e 'm 
_~_~ 0.4 -  
uo  
~'~ 0.2 -  -~ =.__ ', 
~ 0 i i i i i 
0 4 8 12 16 20 24 
Time (wk) 
Changes from baseline in patient global assessment score, measured on 
a 4-point Likert scale (0 = not effective to 3 = maximally effective), after 
4-week administration of sodium pentosan polysulfate (NaPPS) or Ringer's 
solution (control) in patients with osteoarthritis of the knee. P versus con- 
trol group: *=0.002; t<0.001; ~=0.001; §=0.006. 
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of patients aged 65 years or older, or mean BMI were found. Although the mean 
disease duration was numerically less in responders compared with nonrespond- 
ers (3.9 vs 5.8 years), the difference was not statistically significant. 
ADL Funct ion  Parameters  
Of the ADL functions shown in Table II, self-dressing, washing and drying 
self, and bending to pick up clothing were found to be unaffected by the disease 
state at baseline (ie, ~13% of patients in both groups reported any difficulty at 
all in undertaking these tasks). For the remaining 10 ADLs, improvements in
only 3 ADLs in the NaPPS group were greater compared with those in the con- 
trol group at 24 weeks. 
The mean score for ability to get into and out of bed was significantly higher 
in the NaPPS group compared with the control group at all time points (all, P ___ 
0.006) (Figure 4A). The mean change from baseline score for walking outdoors 
on flat ground was significantly higher in the NaPPS group compared with that 
in the control group at all time points (all, P ___ 0.013) (Figure 413). Improvements 
in scores for walking downhill  were significantly greater in the treated group 
4 and 8 weeks after cessation of treatment compared with controls (P = 0.02 and 
P = 0.03, respectively) but not at weeks 16 or 24 (Figure 4C). There were no sig- 
nificant between-group differences in the other 4 walking ability assessments 
(walking immediately after rising, walking uphill, walking upstairs, and walking 
downstairs), difficulty rising from sitting, or difficulty doing domestic chores 
(data not shown). 
When all of the ADL function assessments were aggregated into a single func- 
tional score (as change from baseline), the mean aggregate change from baseline 
score was significantly higher in the NaPPS group compared with the control 
group at 8 and 12 weeks (both, P = 0.02) (Figure 4D). 
Tolerability 
No evidence of hematologic or biochemical abnormalit ies were identified on 
analysis of blood samples before or after trial end (data not shown). Mild bruis- 
ing at the injection site occurred in <1% of patients in each treatment group. No 
other adverse effects were recorded. 
DISCUSSION 
The results of this pilot study suggest hat under controlled, double-blind con- 
ditions, 4 consecutive weekly IM injections of NaPPS 3 mg/kg improved joint 
stiffness, pain at rest, and patient assessment of the effectiveness of treatment 
for up to 20 weeks after treatment cessation, and pain on walking (as a fre- 
quency of response in patients with VAS score _>2 cm) for 4, 12, and 20 weeks 
after treatment cessation. The aggregate ADL function scores were also signifi- 
cantly improved at weeks 8 and 12 for the group administered NaPPS. These 
findings suggest hat the drug could improve functional disability in OA. 
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Figure 4. 
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sulfate. P versus control group: *=0.006; t<0.001; ~=0.002; §=0.003; 11=0.009; 
I=0.013. (cont inued) 
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Figure 4. 
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(Continued) Changes from baseline in funct ion performing activities of daily 
living, measured on a 10-cm visual analog scale (VAS) (0 = no dif f iculty or 
pain to 10 = worst  imaginable di f f iculty or pain) for  (C) walk ing downhi l l  
and (D) aggregate of all funct ional  scores after 4-week administrat ion of 
sodium pentosan polysulfate (NaPPS) or Ringer's solution (control)  in 
patients w i th  osteoarthrit is of the knee. P versus control  group: #=0.02; 
**=0.03. 
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Although the effectiveness of the drug in reducing walking pain was signifi- 
cant only at 4, 12, and 24 weeks after the end of NaPPS treatment in the fre- 
quency of response analysis, examination of the ADL outcomes indicated that 
the NaPPS-treated patients were generally more active and therefore might be 
subjecting their joints to more weightbearing stresses compared with before 
treatment. When overall treatment effectiveness and pain on walking were used 
as markers of response to therapy, the data suggested that patients with short 
(~5 years) disease duration and grade 1 radiographic hanges in their knee 
joints responded better to NaPPS treatment compared with patients with more 
severe disease. However, additional studies are required to confirm this finding. 
In addition, the study was likely underpowered statistically: power calculations 
using the validated WOMAC OA scoring system 26 indicated that for an improve- 
ment ___2 cm on the VAS, 80 patients would be needed in each group. 
Because NaPPS is not an analgesic and is cleared from the plasma within 
12 hours and from body tissues within a few weeks of administration, 21 we can 
suggest hat the symptom relief reported by patients for up to 20 weeks after 
the end of administration might have been related to NaPPS modification of 
some aspects of OA pathobiology associated with clinical symptoms. This sug- 
gestion is consistent with those from laboratory and animal model studies 19-21 
that found that NaPPS was associated with reduced joint inflammation, improved 
blood flow in subchondral bone and soft tissues, and preserved proteoglycan a d 
hyaluronan concentrations in articular cartilage and synovial fluid. 21 
The anti-inflammatory activity of NaPPS was first reported by Kalbhen 27 
using a rat model. Based on the findings, this investigator suggested that the 
anti-inflammatory activity of NaPPS was largely mediated by its ability to resta- 
bilize "leaky" peripheral vasculature and improve microcirculation i the tis- 
sues of affected joints. Anticomplement activity and a subsequent reduction in 
humoral mediators of inflammation were later reported in 16 patients with 
hypercomplementemia, 28 defined as blood total fatty acid esters >746 mg/dL 
and total cholesterol >365 mg/dL and in rabbits with myocardial injury admin- 
istered NaPPS 100 mg IM. 29 
In another study, 15 elderly patients with high blood viscosity and filterability 
were markedly improved with the use of NaPPS 50 mg IM BID. 3° However, it was 
reported that the metabolism of 14C-arachidonic a id cultured with leukocytes 
isolated from the blood of these patients was modified by the drug. Seven days 
after NaPPS administration, the concentrations of arachidonic acid-derived 
lipoxygenase (LOX) metabolites released from these cells were significantly 
lower compared with before treatment. In contrast, arachidonic acid metabo- 
lites generated by the COX pathway were increased. The reduced levels of LOX 
metabolites produced by the leukocytes in patients treated with NaPPS could 
be associated with diminished production of leukotrienes, such as 5HETE, 
diHETEs, and LTB 4. LTB 4 is a particularly potent proinflammatory mediator 
stimulating neutrophil adhesion, chemotaxis, and degranulation. 31 In addition, 
LTB 4 can induce the synthesis of interleukin-8 and platelet-activating factor, 
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which can also perpetuate the inflammatory process. 31,32 In addition to their 
proinflammatory effects, leukotrienes also promote vasoconstriction and 
vascular permeability. 32 In the study in elderly patients mentioned earlier, 
Freyburger et al 3° found that the elevated production of prostaglandin concen- 
trations by leukocytes in these patients treated with NaPPS might not have 
been the result of a stimulatory effect of NaPPS on the COX enzymes directly, 
but instead might have occurred by "shunting" of the arachidonate metabolism 
into this pathway after inhibition of the LOX cascade. Regrettably, the investi- 
gators in that 1987 study did not report which prostaglandins were elevated 
during treatment. 3° Therefore, it is not possible to determine whether the ef- 
fects of NaPPS were selective or influenced by both COX-1 and COX-2. If COX-1 
production was enhanced, NaPPS could possibly confer some gastrointestinal 
protection. 32
Although down-regulation of inflammatory mediators within the tissues of 
joints affected by OA could account for some of the useful clinical effects noted 
in the present study, NaPPS also exhibits other pharmacologic activities that 
could be just as significant. 
PPS has been used in Europe for >40 years as a thromboprophylactic and 
antilipidemic agent. 33 The literature accumulated over that time has indicated 
that pentosan mobilizes vascular occlusions by promoting fibrinolysis, reduc- 
ing fibrinogenesis, and clearing plasma lipids by stimulating lipase release by 
the endothelium. 2°,21 
Intravascular lipid and thrombi have been reported to be often present in 
the arterial and venous microvasculature of heads of femur removed at the 
time of total joint replacement surgery for OA. 34'35 The venous stasis and 
hypertension resulting from the presence of these emboli in OA joints have 
been reported to be associated with bone ischemia and osteonecrosis. 36,37 
These pathologic events have been cited as possible causes of pain in OA, 
and the aim of early surgical treatment of OA was to release the arterial pres- 
sure by fenestration of the subchondral  compartment of the affected 
joint. 38,39 
The antilipidemic and profibrinolytic effects of NaPPS have been reported 
in a group of 11 postmenopausal women with mild to moderate OA. 4° In that 
study, the lipolytic parameters  were monitored before drug treatment and 
8 and 24 hours after they received the first of 4 weekly IM injections of NaPPS 
3 mg/kg. Plasma concentrations of lipoprotein lipase, hepatolipase, and 
superoxide dismutase were significantly elevated between 2 and 4 hours 
after drug administration. 4° NaPPS treatment was associated with modifica- 
tions in peripheral blood mononuclear cell procoagulant activity (MPA) and 
differential leukocyte counts. Patients' MPA, which before drug treatment 
was higher compared with those in non-OA controls, was significantly 
reduced to within the normal range 24 hours after NaPPS administration. 
This effect was maintained for 4 weeks after the end of administration of the 
drug. 4° Although that clinical study was unblinded, the 11 patients with OA who 
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completed the course of 4 weekly injections of NaPPS reported significant clin- 
ical improvement of their symptoms for up to 12 weeks after the last injection. 41 
In other studies, 2 or more intra-articular 50-mg injections of NaPPS into the 
joints of 14 patients with rheumatoid arthritis 42 and 28 patients with OA 43 were 
associated with a clinically significant increase in synovial fluid hyaluronan MW 
of 70% to 83%, probably resulting from a direct stimulatory effect on synovial 
fibroblasts. 21,44 The MW and concentration of hyaluronan i  the synovial fluid of 
joints affected by OA are reduced, 45 and the normalization of these parameters 
by NaPPS could serve to improve the rheologic and cartilage-protective effects 
of synovial fluid, as has been found with the intra-articular administration of
exogenous high-MW hyaluronan. 44 Cartilage hyaluronan and proteoglycans 
have also been found to be preserved in the joints of animal models of OA after 
IM administration of NaPPS. 21 
PPS appears to have pharmacologic a tivities that could be beneficial in OA- 
affected joint tissues. However, because the metabolic imbalances associated 
with the pathophysiology of OA are promulgated by etiologic factors (eg, aging, 
genetic, mechanical) that cannot be directly influenced by the pharmacologic 
effects of a drug, with time, clinical symptoms might return. The results of the 
present study suggest hat 8 to 12 weeks after the end of drug treatment repre- 
sents the time frame for the pathology associated with symptoms to become 
reestablished, but as was expected, this time frame was found to vary from pa- 
tient to patient. 
Although the strength of this study was that it was undertaken using double- 
blind, randomized conditions, there are limitations to its interpretation, partic- 
ularly relating to its high withdrawal rate. The study duration was partly 
addressed by using an ITT analysis. However, there was a considerable 
between-group difference in loss to follow-up, with a greater proportion of con- 
trois not returning. Many of these patients ought other treatments, including 
joint injections of corticosteroids or hyaluronan, or joint replacement surgery. 
These patients were considered to be treatment failures. 
There were no significant between-group differences in baseline characteris- 
tics apart from the mean duration of symptoms, with a difference of 1.8 years. 
This difference was considered unlikely to be clinically significant in view of the 
4 other criteria of disease activity that were statistically similar between the 
groups. Finally, because the patients were selected volunteers, the results 
might not be applicable to all patients with OA of the knee. 
Further longer-term clinical and radiologic studies are required to confirm 
these suggestions and to assess the ability of NaPPS to preserve joint articular 
cartilage, as has been found in animal models of OA. 
CONCLUSIONS 
In this pilot study, 4 weekly injections of NaPPS were associated with signifi- 
cantly improved uration of joint stiffness and pain at rest compared with con- 
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trols for 20 weeks after the cessation of treatment, and significantly improved 
overall function for 8 weeks after the cessation of treatment in these patients 
with OA of the knee. 
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